Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889377 | 0.93 | PRCP (0.33) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL890203 | 0.87 | PRCP (0.36) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL889381 | 0.87 | PRCP (0.36) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL890251 | 0.87 | PRCP (0.37) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL10150949 | 0.86 | PRCP (0.43) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL10150951 | 0.84 | PRCP (0.41) | PRCPPTGESHCRTR1HCRTR2 | |
| SCHEMBL889363 | 0.84 | PREP (0.35) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL10150928 | 0.83 | PRCP (0.39) | PRCPPTGESCHEK2HCRTR1HCRTR2 | |
| SCHEMBL22361591 | 0.82 | HCRTR1 (0.42) | PRCPCHEK2HCRTR1HCRTR2 | |
| SCHEMBL10121382 | 0.82 | HCRTR1 (0.42) | PRCPCHEK2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | PRCP 289/4885PTGES 1672/4885CHEK2 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.